Clinical trials: E.Coli Infections
Extended Spectrum Beta Lactamases (ESBL) E. Coli
Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli
This study is to identify and isolate well-defined microbials (non-ESBL E. coli) in an observational setting exploring natural gastrointestinal decolonization of humans colonized with ESBL E. coli.
- Trial name
- NCT04764500
- Testing
- examination of stool sample, patient questionnaire, examination of blood sample
- Where
- Switzerland
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Escherichia Coli Diarrhea
Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
The purpose of this study is to determine if the ETEC vaccine ETVAX with and without dmLT adjuvant is safe and immunogenic in adults, children, toddlers and infants in Bangladesh.
- Trial name
- ETVAX/dmLT (NCT02531802)
- Testing
- ETVAX, dmLT, Bicarbonate Buffer
- Where
- Bangladesh
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- PATH
Infection, Achlorhydria
Clinical Experiment of Helicobacter Pylori Transmission
The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli.
- Trial name
- NCT00550368
- Testing
- Biological intervention: Enteropathogenic E. coli
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
This phase IV clinical study was designed to evaluate the safety and immunogenicity of the recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 65 years of…
- Trial name
- NCT02417597
- Testing
- Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Recurrent Urinary Tract Infections
Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health…
- Trial name
- BIrUTI (NCT04846803)
- Testing
- ABU bladder lavage, Saline bladder lavage
- Where
- 2 sites in Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Condylomata Acuminata
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
This phase I clinical study was designed to evaluate the safety and immunogenicity of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 18-55…
- Trial name
- NCT02405520
- Testing
- low dosage HPV Vaccine, medium dosage HPV Vaccine, high dosage HPV Vaccine
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Diarrhea
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD)…
- Trial name
- NCT00328380
- Testing
- Rifaximin
- Where
- 3 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Polio
Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
In this study, the safety and tolerability of inactivated polio vaccine (IPV) co-administered with dmLT will be assessed, as well as whether co-administration of dmLT with IPV enhances mucosal responses compared to those with IPV…
- Trial name
- NCT04232943
- Testing
- Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV)
- Where
- Belgium
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- PATH
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles, Rubella
- Trial name
- NCT05279248
- Testing
- HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m）
- Where
- 2 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Hepatitis E
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）
The purpose of this study is to determine the safety and immunogenicity of the recombinant hepatitis E vaccine in people older than 65 years, and evaluate the efficacy of hepatitis E vaccine in this population.
- Trial name
- NCT02189603
- Testing
- Recombinant (E. Coli) Hepatitis E Vaccine
- Where
- China
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Healthy Volunteer
Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea worldwide. Vaccines and therapeutics are under development to prevent ETEC disease in children and travelers.
- Trial name
- NCT03040687
- Testing
- Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diarrhea, Gastroenteritis
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
Although the existing diarrhoeagenic Escherichia coli (E. coli) challenge model is already suitable for dietary interventions in its current form, further characterization of the working-mechanism of the attenuated strain and…
- Conditions
- Diarrhea, Gastroenteritis, Bacterial Infections, Escherichia Coli Infections
- Trial name
- CORAL (NCT02541695)
- Testing
- E. coli strain E1392-75-2A
- Where
- 2 sites in Netherlands
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin®.
- Trial name
- NCT03365921
- Testing
- Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Infantile Diarrhea
Prophylaxis of Gastrointestinal Infections With EcN
This interventional trial shall investigate the efficacy and tolerance of a suspension with non-pathogenic probiotic E. coli strain Nissle (EcN) on prophylaxis against gastrointestinal infections in newborn and infants.
- Trial name
- PIURA (NCT01469273)
- Testing
- Mutaflor® Suspension
- Where
- 3 sites in Peru
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Hospital San Bartolome
Infections
E. Coli Nissle 1917 - Suspension for Infection Prophylaxis
This study evaluates the long term effects of E. coli strain Nissle 1917 (EcN-Suspension) probiotic bacteria administration on the number of both, bacterial and viral infections during the first 24 months of infant's life.
- Trial name
- RONi (NCT02802059)
- Testing
- EcN-Suspension
- Where
- 6 sites in Germany, Poland
- Volunteers
- 567 people, healthy volunteers welcome
- Sponsor
- Ardeypharm GmbH
Gastroenteritis, Bacterial Infection
The Effect of Probiotics on E. Coli Gastroenteritis
Background: The incidence of gastrointestinal infections is very high. In European countries 10-25% of the population suffers from at least one foodborne infection per year.
- Conditions
- Gastroenteritis, Bacterial Infection, Diarrhea
- Trial name
- PRETEC (NCT01225042)
- Testing
- probiotics
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Escherichia Coli Infections
Enteroaggregative E.Coli (EAEC)
Enteroaggregative E. coli (EAEC) is a bacterium that can cause diarrhea. The purposes of this study are to: determine how much EAEC is needed to cause diarrhea in a healthy person, determine if a genetic factor is important in…
- Trial name
- NCT00362869
- Testing
- Levofloxacin, Enteroaggregative E. coli (EAEC)
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Escherichia Coli Infection
Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea
The purpose of the study is to determine if immunization with a recombinant E. coli protein, dscCfaE, is safe and immunogenic when administered through the skin using a patch.
- Trial name
- NCT01382095
- Testing
- Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Enteritis; Escherichia Coli, Enterotoxigenic
Challenge Study of an ETEC Vaccine
The purpose of the study is to determine the efficacy of a vaccine against enterotoxigenic E. coli (ETEC)-caused diarrhea.
- Trial name
- NCT01922856
- Testing
- LTR192G with dscCfaE, No Intervention
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
E.Coli Infections, Bloodstream Infection
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.
- Trial name
- NCT05277350
- Testing
- SNIPR001
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SNIPR Biome Aps.